TheWookly
  • Home
  • News
  • Politics
  • Business
  • Culture
  • Opinion
  • Lifestyle
No Result
View All Result
TheWookly
Home Top News

Not Just Remade Sivir, Covid-19 Pills, And Inhalers Can Soon

Sandra Williams by Sandra Williams
October 13, 2021
in Top News
0
Not-Just-Remade-Sivir-Covid-19-Pills-And-Inhalers-Can-Soon-1
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Treating Covid-19 can now be uncomplicated than ever thought with the new generation of treatments- inhalers, nasal sprays, and pills can be successful treatment tools for the deadly Covid-19 virus.

The dependency on expensive and invasive drugs for treating the Covid-19 virus will not go a long way now as the new form of medications will take the front row.

Related posts

Matt Bomer's

Matt Bomer’s Bio, Childhood, Marriage, Height, Age, Weight, Social Media, And More

March 30, 2022
chris rock

Chris Rock American Comedian Bio,Career,Marrige,Net Worth,Height,Weight,Social Media

March 30, 2022

Not Just Remade Sivir, Covid-19 Pills, And Inhalers Can Soon

Biotech and pharma companies are devotedly working on easy alternative treatments for the virus. 

Merck and Ridgeback Biotherapeutics are all set to release their first-ever pill for the treatment of Covid-19. Merck on Monday asked for approval from the FDA for its antiviral pills.

Not Just Remade Sivir, Covid-19 Pills, And Inhalers Can Soon

The pills were found to minimize the risk of death and hospitalization among adults infected with mild to moderate Covid-19. 

The pharma companies have asked for approval from the US Food and Drug Administration.

The antiviral pills for treating the deadly Covid-19 virus may get the green signal within a few weeks if the data submitted is good enough to prove its safety and efficacy.

So far, Remdesivir being the only medical treatment for Covid-19 was highly expensive and inaccessible to many. Remdesivir is an antiviral drug that is administered via injection. It is effective in ensuring faster recovery among hospitalized Covid-19 patients.

Apart from Remdesivir, Monoclonal antibodies are also permitted to be used in emergency situations. The antibodies help in preventing patients with mild to moderate Covid-19 from developing severe Covi-19. The drug is administered in two ways- injections or infusions.

Along with facile treatment, the pills will also come out to be cheaper than antibody infusions. The antibody infusion is available free of cost to American citizens. However, it costs the US government a whopping $1000 per dose.

It must be well understood that these pills and inhalers cannot replace vaccines. But Covid-19 can now be treated easily with a few antiviral pills.

The antiviral pill, Molnupiravir, by Merck was originally Formulated for the Treatment of Flu. Now the antiviral pills are under evaluation for being a potential treatment for mild to moderate Covid-19 infection. 

The study for its evaluation included about 1,900 volunteers, and results show that the pills effectively reduce the risk of hospitalization or death to half.  

Merck earlier this month announced the results and said, ” the volunteers received 40 pills in total for five days- Four capsules twice a day. It was observed that the pills reduced the risk of hospitalization or death among a group of about 385 people.” 

Merck’s pills come under the class of antiviral drugs, nucleosides. These drugs block the replication of the virus inside the cells. Apart from Merck and Ridgeback Biotherapeutics, two other companies, Roche and Atea Pharmaceuticals, are collaboratively working on a nucleoside pill. 

A drug called AT-527 proves to reduce the amount of present virus among hospitalized patients with moderate Covid-19 infection. Roche is waiting for the results of the study that was conducted on 1,400 volunteers. The reports are expected to arrive before the end of the year. 

Related

Tags: Featured

POPULAR NEWS

  • Torroband-review

    Torroband Reviews – For Total Body Workout Solution?

    0 shares
    Share 0 Tweet 0
  • 10 Meal Prep Ideas for Vegans

    0 shares
    Share 0 Tweet 0
  • Master Needs Some Help! Release Date

    0 shares
    Share 0 Tweet 0
  • Q2 2022 HCA Healthcare, Inc. Earnings Forecast for (NYSE:HCA) released by SVB Leerink

    0 shares
    Share 0 Tweet 0
  • B. Riley Financial: Capital markets activities fuel long-term revenue growth (NASDAQ:RILY)

    0 shares
    Share 0 Tweet 0
Facebook Twitter Youtube Pinterest

Useful Links

  • About
  • Contact
  • Advertise
  • Privacy Policy
  • Disclaimer
  • Terms and Conditions

About Us

Let it be entertainment, business, politics, or tech, The Wookly provides you with the latest news about everything happening all around the globe.

Copyright © 2022 TheWookly. All Rights Reserved

No Result
View All Result
  • Home
  • Politics
  • News
  • Business
  • Culture
  • National
  • Sports
  • Lifestyle
  • Travel
  • Opinion

Copyright © 2022 TheWookly. All Rights Reserved

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
SAVE & ACCEPT